Last reviewed · How we verify
NCT06927089
Non-Invasive Hemodynamic Monitoring of MV ILD Patients With ARF
trial in Interstitial Lung Disease (ILD) in 100 participants. Not yet recruiting.
1 December 2025
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 16 August 2025 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across Egypt |
Conditions studied
- Interstitial Lung Disease (ILD) — all drugs for Interstitial Lung Disease (ILD) →
Sponsor
Assiut University
Who can join
Adults 18 to 80, any sex, with Interstitial Lung Disease (ILD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-invasive hemodynamic monitoring of interstitial lung disease (ILD) patients admitted to respiratory ICU with acute respiratory failure and differentiate according to different modes of mechanical ventilation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06927089
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Interstitial Lung Disease (ILD)
Currently open trials in the same condition.
- NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT07500818 — Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease · NA · recruiting
- NCT06992661 — A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Intersti · Phase 1 · recruiting
- NCT06685874 — Interstitial Lung Disease Exacerbations Study · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06927089 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06927089.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing